PHi is a complete difference maker.

Standard PSA testing has long been a valuable diagnostic tool. But now with the Prostate Health Index (PHi), at-risk men can get a more complete screening regimen for the detection and management of their Prostate Cancer risk.

Shrinking the “gray zone”:
the difference between PSA alone and PHi.

Good. Thumbs up icon

PSA is a valuable screening marker, but it is not specific to prostate cancer.

PSA can be elevated due to benign prostate enlargement or inflammation, which may lead to additional testing and biopsy even when cancer is not present.

Better. Two thumbs up icon

PHi (Prostate Health Index) is a blood test designed to improve risk assessment beyond PSA alone.

PHi combines total PSA, free PSA, and p2PSA ([-2]proPSA) into a single score that more accurately estimates the likelihood of prostate cancer—particularly when PSA falls in the commonly encountered “gray zone” (often 4–10 ng/mL).

How PHi screening makes a difference:


Drop target icon

Improves risk stratification
compared with PSA alone

Drop user plus icon

Supports more informed biopsy decisions,
especially in the PSA gray zone

Drop down arrow icon

Reduces unnecessary biopsies
(reported reductions up to ~30% in appropriate patients)
FDA Approved

PHi is FDA-approved and is included in NCCN1 early detection guidance.


1 NCCN (National Comprehensive Cancer Network) is a not-for-profit alliance of 33 leading cancer centers
Clipboard icon

PHi results should be interpreted by a clinician in the context of age, exam findings, family history, and other risk factors.


1 Disclaimer: This information is not a substitute for medical advice.